NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free ORTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.70▼$16.7050-Day Range$16.40▼$16.7052-Week Range$4.24▼$16.72VolumeN/AAverage Volume157,287 shsMarket Capitalization$380.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Orchard Therapeutics alerts: Email Address Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? It's true.Click here to register for free. About Orchard Therapeutics Stock (NASDAQ:ORTX)Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..Read More Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? It's true.Click here to register for free. ORTX Stock News HeadlinesMay 29, 2024 | msn.comZara opens largest Chicagoland location at Old Orchard in SkokieMay 29, 2024 | msn.comION Orchard marks 15 years as a premier retail destinationMay 28, 2024 | msn.com21-year-old arrested on felony charges after Saturday crashes in Port OrchardMay 28, 2024 | msn.comPort Orchard woman injured, flown to Harborview after crash outside BelfairMay 28, 2024 | msn.comGiant flip flop taken from surf shop in Old Orchard Beach, MaineMay 27, 2024 | msn.comGiant flip flop missing from Old Orchard Beach surf shopMay 26, 2024 | msn.comMeghan Markle's Other Option With American Riviera OrchardMay 25, 2024 | msn.comRick Bayless opens Tortazo at Westfield Old Orchard. See photos from the grand openingMay 24, 2024 | msn.comCherry Orchard families ‘delighted’ as HSE reverses decision to relocate elderly residentsMay 24, 2024 | sg.style.yahoo.comHOKA opens first Singapore brand store at ION OrchardMay 24, 2024 | msn.comUltimatum date set for Orchard Mesa PoolMay 23, 2024 | msn.comWoman dies in Orchard Mesa murder-suicideMay 23, 2024 | msn.comMeghan Markle reduced to tears over ‘unfair criticism’ of American Riviera Orchard, royal expert claimsMay 23, 2024 | finance.yahoo.comPathology & Cytology Laboratories Partners with Orchard Software to Provide Superior Pathology ServicesMay 23, 2024 | msn.comMeghan Markle ‘in tears’ over American Riviera Orchard criticismMay 22, 2024 | msn.comMeghan Markle 'Was in Tears' When Her New Lifestyle Brand American Riviera Orchard 'Was Widely Mocked'May 22, 2024 | msn.comOld Orchard businesses gear up for busy summer seasonMay 22, 2024 | msn.comMeghan Markle upset over ‘unfair criticism’ of American Riviera Orchard, royal expert claimsMay 22, 2024 | msn.comBaseball is returning to The Ballpark in Old OrchardMay 21, 2024 | mirror.co.ukMeghan Markle 'in tears' over 'unfair criticism' of American Riviera OrchardMay 21, 2024 | msn.comION Orchard leads charge in sustainable takeaway practicesMay 20, 2024 | msn.comInaugural Port Orchard Mosquito Fleet Fest adds a May event on Bay StreetMay 19, 2024 | msn.comION Orchard dives into gamification amidst experiential retail demandMay 19, 2024 | msn.comMan fatally shot Sunday morning in Plum Orchard area, NOPD saysMay 18, 2024 | mirror.co.ukMeghan Markle set to embark on huge PR campaign to promote American Riviera OrchardSee More Headlines Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$34.00 Low Stock Price Target$16.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-333.90% Pretax Margin-334.54% Return on Equity-74.94% Return on Assets-33.51% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.98 Sales & Book Value Annual Sales$22.66 million Price / Sales16.77 Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book2.16Miscellaneous Outstanding Shares22,760,000Free Float22,099,000Market Cap$380.09 million OptionableOptionable Beta0.55 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Hubert Baburaj Gaspar M.D. (Age 61)Ph.D., CEO, Member of Scientific Advisory Board & Executive Director Comp: $901.42kMr. Frank Edward Thomas (Age 55)President & COO Comp: $763.95kDr. Nicoletta Loggia Ph.D.R.Ph., Chief Technical OfficerDr. Fulvio Mavilio Ph.D.Chief Scientific OfficerMs. Renee T. LeckHead of Investor RelationsBenjamin NavonDirector of Corporate CommunicationsMr. John CerioChief Human Resource OfficerMr. Robin KenselaarSenior VP & GM of EMEA Commercial OperationsMr. Braden ParkerChief Commercial OfficerDr. Leslie Meltzer Ph.D.Chief Medical OfficerMore ExecutivesKey CompetitorsLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMKaleido BiosciencesNASDAQ:KLDO9 Meters BiopharmaNASDAQ:NMTRPolarityTENASDAQ:PTEIQView All Competitors ORTX Stock Analysis - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price target for 2024? 3 equities research analysts have issued 12-month price objectives for Orchard Therapeutics' stock. Their ORTX share price targets range from $16.00 to $34.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The firm had revenue of $1.24 million for the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 74.94% and a negative net margin of 333.90%. When did Orchard Therapeutics' stock split? Shares of Orchard Therapeutics reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? Orchard Therapeutics (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ORTX) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchard Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.